Globus Medical Reports Second Quarter 2016 Results

Audubon, Pennsylvania, UNITED STATES


AUDUBON, Pa., July 26, 2016 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, today announced its financial results for the second quarter ended June 30, 2016.

  • Worldwide sales increased 2.9% as reported to $137.5 million, or 3.1% on a constant currency basis
  • Second quarter net income increased 7.3% to $25.8 million, or 18.8% of sales
  • Diluted earnings per share (EPS) increased 6.9% to $0.27
  • Non-GAAP diluted EPS increased 10.6% to $0.29
  • Non-GAAP Adjusted EBITDA (AEBITDA) was 36.5% of sales
  • Company issues new 2016 guidance for sales of $575 million

David Paul, Chairman and CEO said, “Second quarter sales were $137.5 million, a year-over-year increase of approximately 3%.  The Globus team essentially grew sales along with the overall spine market this quarter but leveraged that top line growth into non-GAAP EPS of $0.29, which was 10.6% higher than the same quarter last year.  Our AEBITDA for the quarter was 36.5% of sales, compared to 35.0% in the second quarter of 2015, marking the eighth consecutive year of mid-thirties AEBITDA margin.

During the second quarter, we continued progress with product development, sales force expansion and made further progress integrating our two most recent acquisitions.  We remain confident in our long term growth prospects and our ability to sustain our industry leading profitability by the continued execution of our strategy of introducing innovative products, expanding our U.S. and international sales footprint, and controlling our expenses.”

Second quarter sales in the U.S. grew by 2.7% over the second quarter of 2015.  International sales increased by 5.7% over the second quarter of 2015 on an as reported basis and 8.1% on a constant currency basis.

Second quarter net income was $25.8 million, an increase of 7.3% over the same period last year. Diluted EPS for the second quarter was $0.27, as compared to $0.25 for the second quarter 2015.  Non-GAAP diluted EPS for the second quarter was $0.29.

The company generated net cash provided by operating activities of $23.0 million and non-GAAP free cash flow of $13.0 million in the second quarter.  Cash, cash equivalents and marketable securities ended the quarter at $390.1 million.  The company remains debt free.

2016 and 2017 Annual Guidance
The company today issued new guidance for full year 2016 sales of approximately $575 million including $10M from the Alphatec International acquisition, and GAAP earnings per share of approximately $1.17. Guidance for non-GAAP diluted EPS, which excludes, among other things, acquisition related items as described below, remains unchanged at $1.20 per share.  The company preliminarily projects 2017 full year sales of $640M including $40M from the acquisition and expects to provide guidance at the fourth quarter call.

Conference Call Information
Globus Medical will hold a teleconference to discuss its 2016 second quarter results with the investment community at 5:30 p.m. Eastern Time today.  Globus invites all interested parties to join the call by dialing:

           
1-855-533-7141         United States Participants
1-720-545-0060         International Participants
There is no pass code for the teleconference.
           

For interested parties who do not wish to ask questions, the teleconference will be webcast live and may be accessed through a link on the Globus Medical website at investors.globusmedical.com.

If you are unable to participate during the live teleconference, the call will be archived until Tuesday, August 2, 2016.  The audio archive can be accessed by calling 1-855-859-2056 in the U.S. or 1-404-537-3406 from outside the U.S.  The passcode for the audio replay is 5041-7612.

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders.

Non-GAAP Financial Measures
To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), management uses certain non-GAAP financial measures.  For example, non-GAAP Adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation, provisions for litigation, and acquisition related items, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense.  Our management also uses non-GAAP Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections.  Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized. Acquisition related items represents the change in fair value of business acquisition related contingent consideration; costs related to integrating recently acquired businesses including but not limited to costs to exit or convert contractual obligations, severance, and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition related professional fees.

In addition, for the period ended June 30, 2016 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP Diluted Earnings Per Share, which represents net income and diluted earnings per share excluding the provision for litigation, acquisition related items, and adjusted for the tax effects of such adjustments.  We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of litigation, acquisition related items, and adjusted for the tax effects of such adjustments, which we believe are not reflective of underlying business trends.  Additionally, for the periods ended June 30, 2016 and for other comparative periods, we also define the non-GAAP measure of Free Cash Flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment.  We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions.  Furthermore, the non-GAAP measure of constant currency sales growth is calculated by translating current year sales at the same average exchange rates in effect during the applicable prior year period.  We believe constant currency sales growth provides insight to the comparative increase or decrease in period sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates.

Non-GAAP Adjusted EBITDA, non-GAAP net income, non-GAAP Diluted Earnings Per Share, Free Cash Flow and constant currency sales growth are not calculated in conformity with U.S. GAAP.  Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with U.S. GAAP.  These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results.  Our definitions of non-GAAP Adjusted EBITDA, non-GAAP net income, non-GAAP Diluted Earnings Per Share, Free Cash Flow and constant currency sales growth may differ from that of other companies and therefore may not be comparable.  Additionally, we have recast prior periods for non-GAAP net income and non-GAAP Diluted Earnings Per Share.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms.  These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends.  Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted.  These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to successfully integrate the international operations acquired from Alphatec, both in general and on our anticipated timeline, our ability to transition Alphatec’s international customers to Globus products, our ability to realize the expected benefits to our results from the Alphatec acquisition, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks.  For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission.  These documents are available at www.sec.gov.  Moreover, we operate in an evolving environment.  New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.  Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements.  Forward-looking statements contained in this press release speak only as of the date of this press release.  We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

 
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
 
   Three Months Ended Six Months Ended
(In thousands, except per share amounts)  June 30,
 2016
 June 30,
 2015
 June 30,
 2016
 June 30,
 2015
Sales  $137,489  $133,570  $276,753  $265,174 
Cost of goods sold  32,856  32,579  64,500  64,686 
Gross profit  104,633  100,991  212,253  200,488 
          
Operating expenses:         
Research and development  11,251  9,081  21,450  17,737 
Selling, general and administrative  52,408  54,506  106,978  106,795 
Provision for litigation  3,056  374  3,056  406 
Total operating expenses  66,715  63,961  131,484  124,938 
          
Operating income  37,918  37,030  80,769  75,550 
Other income, net  418  441  1,178  94 
Income before income taxes  38,336  37,471  81,947  75,644 
Income tax provision  12,530  13,417  28,131  26,942 
          
Net income  $25,806  $24,054  $53,816  $48,702 
          
Earnings per share:         
Basic  $0.27  $0.25  $0.56  $0.51 
Diluted  $0.27  $0.25  $0.56  $0.51 
Weighted average shares outstanding:         
Basic  95,585  94,979  95,491  94,884 
Diluted  96,426  96,049  96,359  95,977 


 
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(unaudited)
 
(In thousands, except par value)  June 30,
 2016
 December 31,
2015
      
ASSETS     
Current assets:     
Cash and cash equivalents  $95,342  $60,152 
Restricted cash  11,235  26,119 
Short-term marketable securities  229,170  220,877 
Accounts receivable, net of allowances of $2,338 and $2,513,
respectively
  74,713  77,681 
Inventories  104,417  105,260 
Prepaid expenses and other current assets  5,420  7,351 
Income taxes receivable  15,132  8,672 
Deferred income taxes    38,687 
Total current assets  535,429  544,799 
Property and equipment, net of accumulated depreciation of $151,752
and $139,144, respectively
  119,077  114,743 
Long-term marketable securities  65,625  48,762 
Intangible assets, net  32,993  33,242 
Goodwill  91,964  91,964 
Other assets  302  590 
Deferred income taxes  24,086   
Total assets  $869,476  $834,100 
      
LIABILITIES AND EQUITY     
Current liabilities:     
Accounts payable  $11,628  $15,971 
Accrued expenses  47,887  53,769 
Income taxes payable  664  763 
Business acquisition liabilities, current  10,101  12,188 
Total current liabilities  70,280  82,691 
Business acquisition liabilities, net of current portion  17,950  21,126 
Deferred income taxes    13,260 
Other liabilities  1,715  1,699 
Total liabilities  89,945  118,776 
Commitments and contingencies     
Equity:     
Common stock; $0.001 par value.  Authorized 785,000 shares; issued
and outstanding 95,650 and 95,320 shares at June 30, 2016 and
December 31, 2015, respectively
  96  95 
Additional paid-in capital  202,797  192,629 
Accumulated other comprehensive loss  (1,736) (1,958)
Retained earnings  578,374  524,558 
Total equity  779,531  715,324 
Total liabilities and equity  $869,476  $834,100 


 
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
 
     Six Months Ended
(In thousands)    June 30,
 2016
 June 30,
 2015
Cash flows from operating activities:       
Net income    $53,816  $48,702 
Adjustments to reconcile net income to net cash provided by
operating activities:
       
Depreciation and amortization    13,698  11,579 
Amortization of premium on marketable securities    2,085  1,370 
Write-down for excess and obsolete inventories    4,536  4,730 
Stock-based compensation expense    5,690  4,669 
Excess tax benefit related to nonqualified stock options    (764) (1,317)
Allowance for doubtful accounts    148  717 
Change in deferred income taxes    1,625  (5,047)
(Increase)/decrease in:       
Restricted cash    14,884  (1,312)
Accounts receivable    2,624  1,591 
Inventories    (3,812) (11,651)
Prepaid expenses and other assets    1,114  (897)
Increase/(decrease) in:       
Accounts payable    (1,707) (66)
Accounts payable to related-party      (5,359)
Accrued expenses and other liabilities    (10,078) (65)
Income taxes payable/receivable    (5,796) 187 
Net cash provided by operating activities    78,063  47,831 
        
Cash flows from investing activities:       
Purchases of marketable securities    (172,886) (143,691)
Maturities of marketable securities    129,495  85,444 
Sales of marketable securities    16,602  39,085 
Purchases of property and equipment    (20,142) (25,126)
Acquisition of businesses, net of cash acquired      (48,016)
Net cash used in investing activities    (46,931) (92,304)
        
Cash flows from financing activities:       
Payment of business acquisition liabilities    (400) (600)
Proceeds from exercise of stock options    3,575  3,015 
Excess tax benefit related to nonqualified stock options    764  1,317 
Net cash provided by financing activities    3,939  3,732 
        
Effect of foreign exchange rate on cash    119  35 
        
Net decrease in cash and cash equivalents    35,190  (40,706)
Cash and cash equivalents, beginning of period    60,152  82,265 
Cash and cash equivalents, end of period    $95,342  $41,559 
        
Supplemental disclosures of cash flow information:       
Interest paid    2  9 
Income taxes paid    $32,214  $31,880 


 
Supplemental Financial Information
 
Sales by Geographic Area:
 
(Unaudited)    Three Months Ended Six Months Ended
(In thousands)    June 30,
 2016
 June 30,
 2015
 June 30,
 2016
 June 30,
 2015
United States    $124,716  $121,487  $252,276  $241,470 
International    12,773  12,083  24,477  23,704 
Total sales    $137,489  $133,570  $276,753  $265,174 


 
Sales by Product Category:
 
(Unaudited)    Three Months Ended Six Months Ended
(In thousands)    June 30,
 2016
 June 30,
 2015
 June 30,
 2016
 June 30,
 2015
Innovative Fusion    $69,442  $71,571  $139,488  $141,941 
Disruptive Technology    68,047  61,999  137,265  123,233 
Total sales    $137,489  $133,570  $276,753  $265,174 


 
Liquidity and Capital Resources:
 
(Unaudited)    June 30,
 2016
 December 31,
 2015
(In thousands)       
Cash and cash equivalents    $95,342  $60,152 
Short-term marketable securities    229,170  220,877 
Long-term marketable securities    65,625  48,762 
Total cash, cash equivalents and marketable securities    $390,137  $329,791 
        
Available borrowing capacity under revolving credit facility    50,000  50,000 
Working capital    $465,149  $462,108 
            

The following tables reconcile GAAP to Non-GAAP financial measures.

 
Non-GAAP Adjusted EBITDA Reconciliation Table:
 
(Unaudited)    Three Months Ended Six Months Ended
(In thousands, except percentages)    June 30,
 2016
 June 30,
 2015
 June 30,
 2016
 June 30,
 2015
Net income    $25,806  $24,054  $53,816  $48,702 
Interest income, net    (602) (278) (1,098) (556)
Provision for income taxes    12,530  13,417  28,131  26,942 
Depreciation and amortization    7,022  5,905  13,698  11,579 
EBITDA    44,756  43,098  94,547  86,667 
Stock-based compensation expense    2,920  2,538  5,690  4,669 
Provision for litigation    3,056  374  3,056  406 
Acquisition related items    (519) 730  155  1,314 
Adjusted EBITDA    $50,213  $46,740  $103,448  $93,056 
            
Net income as a percentage of sales    18.8% 18.0% 19.4% 18.4%
Adjusted EBITDA as a percentage of sales    36.5% 35.0% 37.4% 35.1%


 
Non-GAAP Net Income Reconciliation Table:
 
(Unaudited)     Three Months Ended Six Months Ended
(In thousands)     June 30,
 2016
 June 30,
 2015
 June 30,
 2016
 June 30,
 2015
Net income     $25,806  $24,054  $53,816  $48,702 
Provision for litigation     3,056  374  3,056  406 
Acquisition related items     (519) 730  155  1,314 
Tax effect of adjusting items     (847) (398) (1,072) (614)
Non-GAAP net income     $27,496  $24,760  $55,955  $49,808 


 
Non-GAAP Diluted Earnings Per Share Reconciliation Table:
 
(Unaudited)    Three Months Ended Six Months Ended
(Per share amounts)    June 30,
 2016
 June 30,
 2015
 June 30,
 2016
 June 30,
 2015
Diluted earnings per share, as reported    $0.27  $0.25  $0.56  $0.51 
Provision for litigation    0.03    0.03   
Acquisition related items    (0.01) 0.01    0.01 
Tax effect of adjusting items    (0.01)   (0.01) (0.01)
Non-GAAP diluted earnings per share*    $0.29  $0.26  $0.58  $0.52 
* amounts might not add due to rounding           


 
Non-GAAP Free Cash Flow Reconciliation Table:
 
(Unaudited)    Three Months Ended Six Months Ended
(In thousands)    June 30,
 2016
 June 30,
 2015
 June 30,
 2016
 June 30,
 2015
Net cash provided by operating activities    $23,016  $13,161  $78,063  $47,831 
Adjustment for impact of restricted cash    784  1,312  (14,884) 1,312 
Purchases of property and equipment    (10,776) (17,898) (20,142) (25,126)
Non-GAAP free cash flow    $13,024  $(3,425) $43,037  $24,017 


 
Non-GAAP Sales on a Constant Currency Basis Comparative Table:
 
(Unaudited)    Three Months Ended Reported
Growth
 Currency
Impact on
Current Period
 Constant
Currency
Growth
(In thousands, except percentages)    June 30,
 2016
 June 30,
 2015
   
United States    $124,716  $121,487  2.7%   2.7%
International    12,773  12,083  5.7% $(287) 8.1%
Total sales    $137,489  $133,570  2.9% $(287) 3.1%


 
(Unaudited)    Six Months Ended Reported
Growth
 Currency
Impact on
Current Period
 Constant
Currency
Growth
(In thousands, except percentages)    June 30,
 2016
 June 30,
 2015
   
United States    $252,276  $241,470  4.5%   4.5%
International    24,477  23,704  3.3% $(823) 1.3%
Total sales    $276,753  $265,174  4.4% $(823) 4.7%
 

        

Coordonnées